A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
As scientists who evolve with technology we treat innovation as a way of life, a life we dedicate to improvement and advancement of Safety, Health and Environment.
